Phase I trial evaluating safety and efficacy of intratumorally administered inflammatory allogeneic dendritic cells (ilixadencel) in advanced gastrointestinal stromal tumors

BACKGROUND: The majority of patients with advanced gastrointestinal stromal tumor (GIST) develop resistance to imatinib, and subsequent treatments have limited efficacy. Ilixadencel (allogeneic inflammatory dendritic cells) is a cell-based immune primer injected intratumorally that previously has be...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Immunol Immunother
Auteurs principaux: Fröbom, Robin, Berglund, Erik, Berglund, David, Nilsson, Inga-Lena, Åhlén, Jan, von Sivers, Karin, Linder-Stragliotto, Christina, Suenaert, Peter, Karlsson-Parra, Alex, Bränström, Robert
Format: Artigo
Langue:Inglês
Publié: Springer Berlin Heidelberg 2020
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7568699/
https://ncbi.nlm.nih.gov/pubmed/32535637
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-020-02625-5
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires